Navigation Links
50 Pharma Companies Worldwide Now Use Codexis In Process Development
Date:10/24/2011

FRANKFURT, Germany, Oct. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that one year after launch, its Codex® Screening Kits are in use or evaluation in manufacturing process development at 50 pharmaceutical companies worldwide.  The announcement was made at CPhI  Worldwide, a global pharmaceutical ingredients convention meeting here this week.  

Codex® Screening Kits were introduced in October 2010.  Pharmaceutical and fine chemical companies including Merck, Roche, DSM and Dainippon Sumitomo are among the global customers using Codex® Screening Kits and Codex® Panels to reduce pharmaceutical manufacturing process development time and cost.  

Codexis also said that through September 30, 2011, more than 10,000 kilograms of various enzymes used in commercial pharmaceutical intermediates production processes have been manufactured by the company's enzyme production partners. Smaller 10-100 kilogram quantities, also used in processes to make commercial pharmaceutical intermediates, have been manufactured at its Redwood City, CA facility.

"With a global network of production capabilities established, we are supporting our pharmaceutical and fine chemical customers at every scale, from clinical development to commercial production.  This further demonstrates the utility of Codexis biocatalyst enzymes for the development and commercial production of pharmaceutical products," said Peter Strumph, Senior Vice President and Business Head, Pharmaceuticals.

Codexis is an industrial biotechnology company developing products that make manufacturing processes faster, cleaner and cheaper. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell and for biobased chemicals.  For more information, visit www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the utility of Codexis' biocatalyst enzymes for the development and commercial production of pharmaceutical products. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results.  Important factors known to Codexis that could materially affect actual results include Codexis' dependence on contract manufacturers for commercial scale production of its biocatalysts.  Other factors can be found in Codexis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 3, 2011, including under the caption "Risk Factors."  Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:  
Media:  Lyn Christenson, lyn.christenson@codexis.com, 650.421.8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212.827.3771   Investors:  Henk Adriaenssens, ir@codexis.com, 650.421.8331


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
2. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
3. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
4. Robbins Umeda LLP Announces an Investigation of KV Pharmaceutical Company
5. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
6. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
7. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
8. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
9. Study Finds Children More Likely to Receive Recommended RSV Medication Doses When Administered Through Specialty Pharmacy
10. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
11. Academy of Managed Care Pharmacy Opens 2011 Educational Conference in Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... Blair 36 th Annual Growth Stock Conference in ... Mr. Whelan are scheduled to present at the conference on ... live audio-only webcast of the presentation and related presentation materials ...
(Date:5/31/2016)... , May 31, 2016 ... and Annotate Content From Elsevier,s ScienceDirect Database ... scientific, technical and medical information products and services, ... Berlin -based scientific collaboration platform PaperHive to enable ... over 12 million articles on ScienceDirect , ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... CallTrackingMetrics's software gives ... monitor the performance of sales and support staff, and to efficiently route calls ... allows customers to record, transcribe, route, document, and report on everything going on ...
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international leaders ... spa and beauty in Europe. The organization asked its partner experts in Europe - ... - to forecast where wellness is headed in Europe. Predictions range from European nations ...
(Date:5/31/2016)... ... 2016 , ... Interest is on the rise for using the CRISPR-Cas9 system ... for RNAi hit validation. A key reason may be that high-throughput synthesis—combined with a ... RNA (crRNA) collections in arrayed formats. , Arrayed crRNA screens have ...
(Date:5/31/2016)... ... ... Dr. Charles A. Ditta attained his Doctor of Medical Dentistry Degree from ... where he graduated in the top ten percentile of his class. Dr. Ditta has ... has been a member in good standing for thirty years in the American Dental ...
(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... As the ... for their children and their efforts to keep their households lice free. , ... Hawaii are enacting new policies that keep kids in the classroom despite the fact ...
Breaking Medicine News(10 mins):